Filing summary
Issuer identification: The filing is Global Medical REIT Inc. (NYSE: GMRE), not Chiron Real Estate Inc. It is a Form 10-Q for the quarter ended September 30, 2023, filed November 7, 2023. The unaudited financial statements are presented in thousands of dollars, except per-share data.
Business context and reporting period
Global Medical REIT owns and acquires healthcare facilities and leases them to physician groups and healthcare systems. Its revenue is primarily rent and tenant expense reimbursements, mostly under medium- to long-term leases. The company reported results for the three and nine months ended September 30, 2023, compared with the same 2022 periods.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $35.5 million | $35.4 million | $108.1 million | $101.0 million |
| Net income | $4.8 million | $10.0 million | $21.2 million | $18.1 million |
| Net income attributable to common stockholders | $3.1 million | $8.1 million | $15.6 million | $13.0 million |
| Common earnings per share, basic and diluted | $0.05 | $0.12 | $0.24 | $0.20 |
| FFO per share and unit | $0.22 | $0.23 | $0.64 | $0.70 |
| AFFO per share and unit | $0.23 | $0.25 | $0.69 | $0.74 |
| Operating cash flow | Not stated by quarter | Not stated by quarter | $50.3 million | $58.2 million |
For Q3, expenses were $33.0 million, including $7.2 million of interest expense. For the nine months, expenses were $102.5 million, including $23.9 million of interest expense. The filing does not present an operating margin measure; reported net income includes gains on property sales.
Financial position, debt and liquidity
- At September 30, 2023, total assets were $1.303 billion, net real estate was $1.192 billion, total liabilities were $668.9 million, and total equity was $633.6 million.
- Total debt, net of issuance costs, was $617.6 million, down from $694.1 million at December 31, 2022. Cash and cash equivalents were $1.3 million; restricted cash was $6.3 million. Combined cash and restricted cash was $7.6 million, versus $14.5 million at year-end 2022.
- At November 6, 2023, the company reported $317.6 million of unused revolver capacity. Management said it complied with its credit-facility covenants as of September 30.
- Weighted-average debt interest rate was 3.78% at quarter-end. Interest-rate swaps hedge the term loans; the $68.4 million revolver balance remained unhedged. The filing estimates a 100-basis-point SOFR increase would reduce annual cash flow by approximately $0.7 million, assuming no change in variable-rate debt.
- Common dividends were $0.21 per share per quarter, or $0.63 per share for the nine months. Series A preferred dividends accrue at 7.50% annually. Q3 AFFO per share and unit of $0.23 exceeded the common dividend per share of $0.21; this comparison is not a full measure of dividend coverage.
Changes versus the prior comparable periods
- Q3 revenue was nearly flat year over year, while common earnings per share fell to $0.05 from $0.12. Net income declined by $5.2 million, primarily reflecting a smaller property-sale gain: $2.3 million in Q3 2023 versus $6.8 million in Q3 2022.
- Nine-month revenue rose $7.1 million, but interest expense increased $6.7 million, reflecting higher average borrowings and interest rates. Income before property-sale gains fell $5.8 million. Net income rose $3.0 million, largely because gains on property sales increased to $15.6 million from $6.8 million.
- Nine-month FFO per share and unit declined to $0.64 from $0.70, and AFFO per share and unit declined to $0.69 from $0.74.
- Operating cash flow fell by $7.9 million year over year. Investing cash flow shifted to a $70.7 million inflow from a $135.8 million outflow, reflecting property-sale proceeds and substantially lower acquisition spending. Financing cash flow was a $127.9 million outflow, mainly due to net credit-facility repayments and dividends.
Outlook, commentary and risks
- No specific earnings, FFO or AFFO guidance is provided in the supplied filing text. Management expects to meet liquidity needs through operating cash flow, debt and equity financing, property dispositions and OP Unit issuances.
- The company completed one acquisition for a contractual price of $6.7 million, funded primarily with OP Units, and three property dispositions generating $80.5 million of gross proceeds and $15.6 million of gains. Its portfolio comprised 185 buildings, 4.7 million leasable square feet and $111.4 million of annualized base rent at quarter-end.
- Management cited elevated interest rates and inflation as pressures on borrowing costs, investment capacity and profitability. It also identified tenant rent collection and renewals, healthcare labor costs, tenant reimbursement and reimbursement-policy changes, economic conditions, and access to capital as risks.
- The company had approximately $24.0 million of capital-improvement commitments; approximately $9.7 million was expected in the next 12 months. Management reported no material litigation or known material environmental liability and no material changes to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review the trend in interest expense, unhedged revolver exposure, debt maturities and covenant headroom, particularly as rates and refinancing conditions change.
- Assess whether recurring operating cash flow and AFFO support common and preferred dividends, taking account of capital spending and debt service.
- Distinguish recurring operating performance from property-sale gains when evaluating reported net income.
- Monitor tenant collections, lease renewals and the company’s ability to fund committed capital improvements and future liquidity needs.